Biotech Values

[ThomasS]

MNTA: Let's just hope that MNTA's market cap increases beforehand due to other events. Certainly, we'll have visibility on the M-Enoxaparin issue by then, in addition to a hopefully more settled market.
The NVS connection cannot be ignored for obvious reasons; it seems even more relevant if MNTA's pps doesn't level off at a higher valuation within the next 6 months. I'd imagine that Dr. Wheeler has all eyes focused on getting M-Enox to the market as quickly as possible, or at least getting some clearer path on it to help the pps.
It is also relevant that MNTA will still have some $100M+ in cash come July, which roughly equals a $140M enterprise value by then. IMO, cheap.
(Cash guidance for all of 2008 is, again, $50-$55M)

On the fringe, I wouldn't be surprised to see additional partnering irt additional FoB's. Some of these may be from Sandoz, perhaps from others. If Sandoz, it only highlights the NVS angle further.
(I'm not hoping for a buyout/merger; I would like to see an astronomical rise in a independant MNTA stock.)